Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study Evaluating MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

NCT05076760 is registered in ClinicalTrials.gov with Memgen, Inc. as lead sponsor.

NCT NCT05076760
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05076760 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study Evaluating MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Lead sponsor
Memgen, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
April 21, 2022
Completion date
December 31, 2031
Enrollment
40 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, cutaneous squamous cell carcinoma, head and neck cancer, melanoma, merkel cell carcinoma, metastatic cancer, non small cell lung cancer, pancreatic cancer, solid tumor, triple negative breast cancer